CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CELZDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How CELZ's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CELZ-201 Administration | Phase 2 | Type 1 Diabetes | - | - |
CELZ-201-DDT | Phase 2 | Chronic Low-back Pain | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s (CELZ) pipeline across Phase 2. Its lead program is CELZ-201 Administration (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s next FDA catalyst?→
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s (CELZ) next tracked catalyst is a Phase 2 expected January 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELZ biotech catalysts?→
Add CELZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.